New Approaches for Immunization and Therapy Against Human Metapneumovirus

Overview

Journal Clin Vaccine Immunol

Publisher American Society for Microbiology

Specialties Allergy & Immunology
Pathology

Date 2015 Jun 12

PMID 26063237

Citations 13

Authors

Sherry C Wen

John V Williams

Affiliations

Soon will be listed here.

Abstract

Human metapneumovirus (HMPV) is a paramyxovirus discovered in 2001 in the Netherlands. Studies have identified HMPV as an important causative agent of acute respiratory disease in infants, the elderly, and immunocompromised individuals. Clinical signs of infection range from mild upper respiratory illness to more serious lower respiratory illness, including bronchiolitis and pneumonia. There are currently no licensed therapeutics or vaccines against HMPV. However, several research groups have tested vaccine candidates and monoclonal antibodies in various animal models. Several of these approaches have shown promise in animal models. This minireview summarizes the current therapies used to treat HMPV infection as well as different approaches for immunization.

Citing Articles

Cross-protective antibodies against common endemic respiratory viruses.

Caban M, Rodarte J, Bibby M, Gray M, Taylor J, Pancera M Nat Commun. 2023; 14(1):798.

PMID: 36781872 PMC: 9923667. DOI: 10.1038/s41467-023-36459-3.

Profiling of hMPV F-specific antibodies isolated from human memory B cells.

Xiao X, Fridman A, Zhang L, Pristatsky P, Durr E, Minnier M Nat Commun. 2022; 13(1):2546.

PMID: 35538099 PMC: 9091222. DOI: 10.1038/s41467-022-30205-x.

Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study.

Wang X, Li Y, Deloria-Knoll M, Madhi S, Cohen C, Ali A Lancet Glob Health. 2020; 9(1):e33-e43.

PMID: 33248481 PMC: 7783516. DOI: 10.1016/S2214-109X(20)30393-4.

Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies.

Kinder J, Moncman C, Barrett C, Jin H, Kallewaard N, Dutch R J Virol. 2020; 94(20).

PMID: 32759319 PMC: 7527037. DOI: 10.1128/JVI.01068-20.

Respiratory Virus Infections in Hematopoietic Cell Transplant Recipients.

Pochon C, Voigt S Front Microbiol. 2019; 9:3294.

PMID: 30687278 PMC: 6333648. DOI: 10.3389/fmicb.2018.03294.

References

van den Hoogen B, Herfst S, Sprong L, Cane P, Forleo-Neto E, de Swart R . Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis. 2004; 10(4):658-66. PMC: 3323073. DOI: 10.3201/eid1004.030393. View

Boivin G, Mackay I, Sloots T, Madhi S, Freymuth F, Wolf D . Global genetic diversity of human metapneumovirus fusion gene. Emerg Infect Dis. 2004; 10(6):1154-7. PMC: 3323143. DOI: 10.3201/eid1006.031097. View

FULGINITI V, Eller J, DOWNIE A, KEMPE C . Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA. 1967; 202(12):1075-80. DOI: 10.1001/jama.202.12.1075. View

Kim H, Canchola J, BRANDT C, Pyles G, Chanock R, Jensen K . Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969; 89(4):422-34. DOI: 10.1093/oxfordjournals.aje.a120955. View

Wild C, Oas T, McDanal C, Bolognesi D, Matthews T . A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A. 1992; 89(21):10537-41. PMC: 50374. DOI: 10.1073/pnas.89.21.10537. View

Tristram D, Welliver R, Mohar C, Hogerman D, Hildreth S, Paradiso P . Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis. 1993; 167(1):191-5. DOI: 10.1093/infdis/167.1.191. View

Groothuis J, Simoes E, Levin M, Hall C, Long C, Rodriguez W . Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med. 1993; 329(21):1524-30. DOI: 10.1056/NEJM199311183292102. View

Tang R, Mahmood K, MacPhail M, Guzzetta J, Haller A, Liu H . A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine. 2005; 23(14):1657-67. PMC: 7115684. DOI: 10.1016/j.vaccine.2004.10.009. View

Buchholz U, Biacchesi S, Pham Q, Tran K, Yang L, Luongo C . Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity. J Virol. 2005; 79(11):6588-97. PMC: 1112115. DOI: 10.1128/JVI.79.11.6588-6597.2005. View

10.

Lo M, Brazas R, Holtzman M . Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol. 2005; 79(14):9315-9. PMC: 1168759. DOI: 10.1128/JVI.79.14.9315-9319.2005. View

11.

Williams J, Martino R, Rabella N, Otegui M, Parody R, Heck J . A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J Infect Dis. 2005; 192(6):1061-5. PMC: 1483060. DOI: 10.1086/432732. View

12.

Williams J, Crowe Jr J, Enriquez R, Minton P, Peebles Jr R, Hamilton R . Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults. J Infect Dis. 2005; 192(7):1149-53. PMC: 1476781. DOI: 10.1086/444392. View

13.

Pham Q, Biacchesi S, Skiadopoulos M, Murphy B, Collins P, Buchholz U . Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo. J Virol. 2005; 79(24):15114-22. PMC: 1316028. DOI: 10.1128/JVI.79.24.15114-15122.2005. View

14.

Lamb R, Paterson R, Jardetzky T . Paramyxovirus membrane fusion: lessons from the F and HN atomic structures. Virology. 2005; 344(1):30-7. PMC: 7172328. DOI: 10.1016/j.virol.2005.09.007. View

15.

Williams J, Wang C, Yang C, Tollefson S, House F, Heck J . The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J Infect Dis. 2006; 193(3):387-95. PMC: 1586246. DOI: 10.1086/499274. View

16.

Hamelin M, Prince G, Boivin G . Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother. 2006; 50(2):774-7. PMC: 1366914. DOI: 10.1128/AAC.50.2.774-777.2006. View

17.

Herd K, Mahalingam S, Mackay I, Nissen M, Sloots T, Tindle R . Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice. J Virol. 2006; 80(4):2034-44. PMC: 1367143. DOI: 10.1128/JVI.80.4.2034-2044.2006. View

18.

Skiadopoulos M, Biacchesi S, Buchholz U, Amaro-Carambot E, Surman S, Collins P . Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. Virology. 2005; 345(2):492-501. DOI: 10.1016/j.virol.2005.10.016. View

19.

Wilkesmann A, Schildgen O, Eis-Hubinger A, Geikowski T, Glatzel T, Lentze M . Human metapneumovirus infections cause similar symptoms and clinical severity as respiratory syncytial virus infections. Eur J Pediatr. 2006; 165(7):467-75. DOI: 10.1007/s00431-006-0105-4. View

20.

Ulbrandt N, Ji H, Patel N, Riggs J, Brewah Y, Ready S . Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol. 2006; 80(16):7799-806. PMC: 1563801. DOI: 10.1128/JVI.00318-06. View